Perlmutter Cancer Center

New York, New York 10016

2 studies enrolling now · 6 studies all time

What they study most

Advanced Ovarian Cancer, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Solid Tumors, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, BRCA Mutation, Breast Neoplasms, Cancer, Complete Response

Studies at this site

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment — Recruiting now
• Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS) — Starting soon
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. — Running, not enrolling
• Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma — Paused
• Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors — Stopped early
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed